Cantor Fitzgerald Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)

Cantor Fitzgerald initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR - Free Report) in a report published on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $65.00 price target on the stock.

Separately, Lifesci Capital reaffirmed an outperform rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $85.71.

Structure Therapeutics Stock Performance

Shares of GPCR traded down $2.93 on Tuesday, hitting $41.48. 779,568 shares of the stock traded hands, compared to its average volume of 593,870. The company has a market capitalization of $1.93 billion and a PE ratio of -50.39. The business has a 50 day simple moving average of $41.76 and a 200 day simple moving average of $48.70. Structure Therapeutics has a one year low of $21.79 and a one year high of $75.02.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Friday, March 8th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. On average, equities analysts expect that Structure Therapeutics will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 404.0% during the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company's stock worth $178,216,000 after acquiring an additional 3,504,747 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Structure Therapeutics by 133.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company's stock valued at $95,107,000 after buying an additional 1,333,333 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of Structure Therapeutics by 104.2% during the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company's stock valued at $92,411,000 after buying an additional 1,157,006 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Structure Therapeutics by 835.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company's stock valued at $90,752,000 after buying an additional 1,607,525 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of Structure Therapeutics by 28.5% during the 3rd quarter. FMR LLC now owns 1,590,335 shares of the company's stock valued at $80,185,000 after buying an additional 352,600 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.